

SUBJECT INDEX VOLUME 23 NUMBER S2

A

Abnormal neuroendocrine, S97
 Abstinent male alcoholics, S156
 Academia, S10
 Academically-striving countries, S59
 ACE gene, S130
 ACE I/D polymorphism, S106
 ACTH secretion, S29
 Acute adolescent mania, S124
 Acute major depressive disorder, S113
 Acute schizophrenia, S122
 Addiction, S17, S102
 Administrative arrangements, S9
 Adolescent, S82
 Adrenal hyperplasia, S60
 Adrenal insufficiency, S48
 Adrenalectomy treatment, S145
 β -, α 2-adrenergic receptors, S3
 A2-adrenoceptor supersensitivity, S139
 Adrenoceptor up-regulation, S138
 Adverse early environment, S5
 Affective disorders, S137
 Aggression, S136, S151
 κ agonists, S145
 AIDS, S19, S49–S51, S113
 Alcohol-exposed children, S148
 Alcohol ingestion in the afternoon, S117
 Alcoholics, abstinent male, S156
 Algorithm-based treatment, S68
 Allopregnanolone, S24, S40, S72
 Allotetrahydrodeoxycorticosterone, S24
 Alzheimer's disease, S8, S48, S52, S94, S128
 Ampakines, S84
 Amphetamine receptor antagonists, S118
 Amphetamine, S17
 Amygdala, S77
 β -Amyloid, S52
 Analgesic responses, S145
 Androstadienone, S28
 Angiotensin I-converting enzyme, S106
 Anorexia nervosa, S104
 Anticonvulsant drugs, S3
 Anticonvulsant theory, S89
 Antidepressant effect, S146
 Antidepressant treatment, S26, S103
 Antidepressant trials, S44
 Antidepressants, S23, S42–S44, S74, S95
 Antioxidants, S52, S53
 Antipsychotic drugs, S32, S55, S73
 Antipsychotic therapy, S32–S35, S134
 Antipsychotic treatment, S144
 Anti-saccade performance, S151
 Anxiety, S61, S65, S77, S86, S133
 Anxiety disorders, S5, S6, S56, S64, S76, S104
 Anxiolytic metabolite, S26
 Anxiolytic-hypnotic drugs, S24
 Astrocytes, S131
 Atenolol, S138
 Attention deficits, S152
 Atypical antipsychotic drugs, S14
 Atypical neuroleptics, S55
 Autoimmune disorders, S30
 Autonomic responses, S119
 AVP-neurophysin, S50
 Axis stress responses, S2

B

B12 vitamin, S140
 Beclomethasone-induced vasoconstriction (BIV), S121
 Bed nucleus of the stria terminals, S111
 Behavior problems, S100
 Behavioral effects of NK₁, S23
 Behavioral endocrine responses, S119
 Benign intracranial hypertension, S136
 Benzodiazepine withdrawal syndrome, S124
 Benzodiazepines, S56
 Benzothiophenes, S79
 Bilateral grand mal seizure, S91
 Biochemical markers, S110
 Biogenic amine systems, S43
 Biological Psychiatry, S35
 Biosynthesis, S70
 Bipolar adolescents, S124
 Bipolar disorder, S3, S12, S64, S68, S75, S87, S107, S132
 Blood glucose metabolism, S123
 Body, S8
 Body-mind interplay, S40
 Bone mineral density, S34
 Brain, S92–S94
 Brain aging, S94
 Brain closure function, S152
 Brain damage, S86
 Brain development, S12, S70
 Brain fear circuits, S65
 Brain functions, S140
 Brain plasticity, S36
 Brain redox systems, S52–S54
 Brain regional structures, S64
 Brazilian study, S114
 Bulimia nervosa, S104
 Business ethics, S16

C

C-6 glioma cells, S131
 Calcium-calmodulin kinase type II, S18
 cAMP, S3
 Carbamazepine, S3
 Carbohydrate tolerance, S80
 Carbon monoxide, S30
 CCK-4 induced panic, S157
 Cell biology, S35
 Cell communication, S15
 Central nervous system, S12, S92
 Cephalalgia, S132
 Cerebral function, S67
 Cerebralum®, S127/
 Cerebravascular disease, S127
 Chang, S22
 Channel blockers, S75
 Channel openers, S75
 Chemosensory transduction, S27
 Child, S82
 Cholesterol, S24
 CHR, S49
 Chronic depression, S113
 Chronic fatigue syndrome (CFS), S76, S114

Cigarette smoking, S150
 Circadian salivary cortisol levels, S105
 Circannual melatonin, S108
 Circuitry pharmacotherapy, S73–S75
 Clinical diagnosis, S115
 Clinical Global Impression Scale, S116
 Clinical trials, S43
 Clobazam, S3
 Clonidine administration, S132, S139
 Cloniphen, S78
 Clozapine, S54, S116, S123, S135
 Cocaine, S17, S46, S133
 Cognition, S51, S79, S92–S94
 Cognitive aging, S94
 Cognitive dysfunction, S128
 Cognitive functioning, S8
 Cognitive therapeutic considerations, S99
 Collaboration, S58
 Collegium International
 NeuroPsychopharmacologicum, S9
 Comorbid psychiatric disorders of somatic illness, S143
 Consultation-liaison psychiatry, S100
 Convulsive therapy, S91
 Corticotropin releasing factor, S1, S4, S29, S60, S77, S149
 Corticotropin-releasing hormone, S81
 Corticotropin-releasing hormone system, S124
 Cortisol, S47
 CRF, S6
 CRF cells, S111
 CRF neurocircuits, S63
 CRF receptor antagonists, S5
 CRF₁-selective antagonist, S119
 CRH hypothesis, S6
 CRH system, S76
 CRH type-1 receptor antagonism, S119
 Cultural formulation, S37
 Cultural framework, S95
 Cultural specificity, S45
 Culture, S37
 Cyclic Amp response element binding protein, S18
 Cytokines, S60

D

D-allele, S106
 Daylength variation rate, S108
 Dehydroepiandrosterone, S25, S56
 Delayed-type hypersensitivity, S105
 Dementia, S126, S136
 Depressed men, S147
 Depression ideation, S139
 Depression, S26, S34, S35, S47, S57, S59–S61, S62, S65, S76, S80–S83, S89, S101, S103, S104, S121, S133, S138, S144, S153
 Depression subtypes, S113
 Depressive disorders, S44, S64, S95, S105, S113, S115
 Depressive patients, S130
 Dexamethasone suppression test (DST), S110

Dexamethasone treatment, S145
 Deydroepiandrosterone, S40
 D-Fenfluramine challenge test, S89, S122
 DHEA, S46–S48, S127
 DHEA-S, S25, S127
 Diabetes, S106, S123
 Diencephalic stimulation theory, S90
 Differential gender effects, S32
 Discomfort index, S109
 Diurnal cortisol, S19
 DNA technology, S8
 Dopamine, S17, S35, S53, S93, S118
 Dopamine hormones, S148
 Dopamine neurotransmission, S137
 Dopamine receptor antagonists, S118
 Dopamine receptor D3, S137
 Dopamine receptors D2, S137
 Doxorubicin, S118
 Drug development, S13
 Drug metabolism, S32
 Drugs of abuse, S19
 Dysthymic patients, S113

E

Early-onset schizophrenia, S126
 Eating disorders, S25, S96, S104
 Educational programs, S59
 EEG complexity changes, S125
 EEG sleep, S82
 Efficacy, S42, S43
 Elderly men, S136
 Elderly patients, S126
 Electroconvulsive therapy (ECT), S69, S89–S91, S127
 Electroconvulsive treatments, S62
 ELISPOT technique, S110
 Emotional functioning, S8
 Emotional stressor, S111
 β -END, S117
 Endocrine dysfunction, S34
 Endocrine functions, S80–S83
 Endocrine system, S59
 Endogenous pharmacology, S128
 Environmental factors, S109
 Episodic psychiatric disorders, S3
 Estradiol, S56, S92
 Estrogen, S41, S66, S92–S94, S107
 Estrogen receptor β , S92
 Estrogen replacement therapy, S94
 Estrogen supplementation, S153
 Estrogen therapy, S126
 Estrogen-serotonin link, S98
 Ethanol, S72
 Ethics, S16
 Euthyroid psychiatric subjects, S142
 Evolution, S12
 Experimental psychopathology, S35

F

Federal Drug Administration, S44
 Female depression, S130
 Female rat brain, S109
 Female rats, S112
 Female Sprague-Dawley rats, S109
 Fibromyalgia, S76
 First episode schizophrenia, S110
 Fluoxetine, S26, S130
 Forced migrants, S143
 France, S15, S21
 Free radicals, S52
 Functional brain imaging, S77
 Functional imagery, S15
 Functional imaging, S54

G

GABA mediated inhibition, S26
 GABA_A receptor, S72
 GABA_A receptors gene expression, S24
 GABRA5 gene locus, S136
 Gaddum, S22
 Gender, S32–S35, S123
 Gender differences in brain stems, S64–S66
 Gender specific, S28
 Gene expression, S15, S70
 Gene-related peptide, S118
 General medicine, S102
 General practitioners, S98–S99, S102
 Genetic association study, S136
 Genetic enhancement, S18
 Genetic risk, S12
 Genetics, S7
 Genital herpes, S31
 Geomagnetic factors, S109
 Geomagnetic field, S108
 Geomagnetic index DST, S109
 Germany, S16
 Globalization, S9, S20
 Glucocorticoid antagonists, S56
 Glucocorticoid negative feedback, S65
 Glucocorticoid receptor, S131
 Glucocorticoid receptors antagonists, S59–S61
 Glucocorticoids, S49, S101
 Glucose tolerance, S123
 Glutamate, S93
 Glutamate mechanisms, S83–S87
 Glutamate synapse, S53
 Glycemic peak delay, S123
 Gonadal hormones, S109, S114
 Gonadal steroids, S96, S109
 Gonadectomy, S114
 Gonadotropins, S28
 Government, S43
 Governmental agencies, S10
 Grand mal seizure, S91
 Growth hormone, S82
 Growth hormone-releasing hormone, S80, S81, S82
 GSK-3 β , S38
 Gynecology and psychiatry, interface between, S96–S98

H

Haloperidol, S54, S89, S150
 Haloperidol treatment, S123
 Health care, S7
 Health care aspects, S15–S16
 Health care policy, S7
 Healthy smokers, S134
 Help-seeking Pathways, S95
 Heterosexuals, S120
 High melatonin excretors, S107, S138
 High risk subjects, S117
 High-resolution imaging, S126
 Hippocampal CA1 pyramidal cells, S92
 Hippocampal circuitry, S92
 Hippocampus, S17, S38, S90
 Hippocrates, S100
 HIV, S18, S19
 HIV-1 infection, S51, S133
 Hormonal interventions, S14
 Hormonal replacement therapy, S14, S45, S66
 Hormones, S18–S20, S56–S57
 HPA axis, S111
 HPA system, S32, S130
 HPA-axis, S117
 5-HT₃ receptor, S71
 5-HT receptor sub-types, S115

5-HT-1A receptor, S91
 Human sexuality, S94–S95
 Hydrocortisone treatment, S124
 Hypercortisolism, S60
 Hyperforin, S88
 Hypericum perforatum, S88
 Hyperprolactinemia, S33
 Hypogonadal men, S147
 Hypothalamic-pituitary-adrenal (HPA) axis, S2, S6, S14, S29, S30, S35, S50, S60, S65, S76, S88, S146
 Hypothalamic-pituitary-gonadal (HPG) axis, S66
 hypothalamic-pituitary-thyroid (HPT) axis, S67, S69
 Hypothalamo-pituitary-adrenal (HPA) system, S80
 Hypothalamus, S57, S91
 Hypothyroidism, S106

I

I/D polymorphisms, S130
 Idiographic fomulation, S95
 IGF-1, S118
 Immune function, S19
 Immune system, S18–S20, S101
 Immunity, S31
 Impaired glucose tolerance, S123
 Impulsivity, S134
 Insomnia, S104
 Insurance, S16
 Interferon- α , S133
 Intervention, S99
 Intracellular messengers, S3
 Intravenous drug use (IDU), S113
 Intravenous infusion of sodium lactate, S135
 Ischemic brain damage, S86

K

Ketamine, S86
 Kraepelin, S123, S140

L

Lamotrigine, S3
 Latency, S146
 LC/NE system, S76
 Learning, S18
 Learning disabilities, S106
 Learning/memory performance, S114
 Leeman, S22
 Legislation, S21
 Levothyroxine, S68
 Lithium, S39, S57, S62, S69
 Lithium prophylaxis, S87
 Lithium response, S124
 Lithium treatment, S156
 Long-term depression, S17
 Long-term potentiation (LTP), S17, S125
 Lordosis quotient, S112
 Low melatonin depressives, S140
 Low melatonin excretors, S107, S138
 Low risk subjects, S117
 Low serum triiodothyronine, S142
 Lymphocytes, S110

M

Maghrebian psychiatry, S21
 Magnetic resonance spectroscopy, S90, S126
 Major depressive disorder, S44, S64, S105, S113, S115

Major psychiatric disorders, S136
 Male depression, S130
 Male dysthymia, S147
 Management of depression, S103
 Manic depression, S39, S106
 Maprotiline, S130
 Maternal care, S13
 Medical ethics, S16
 Mediterranean, S20–S21, S45
 Medullary neurons, S111
 Melatonin, S107, S108, S139, S140, S154
 Memory, S18, S140
 Memory training, S106
 Menopause, S45, S98, S153
 Menstrual cycle, S40, S155
 Menstrual dysfunction, S33
 Menstrually-related disorders, S26
 Mental and neurological illnesses, S104
 Mental disorders, S24–S27, S102
 Mental health, S98
 Mental health advocacy, S11
 Mental health programs, S9
 Mental health responsibility, S98
 Mental health services, S999, S102
 Mesolimbic dopamine system, S17
 Metabolic functioning, S15
 Metabolic syndrome, S76
 Metabotropic glutamate receptor agonists, S84, S86
 Metabotropic glutamate receptors, S86
 Metastatic breast cancer, S19
 Methamphetamine, S52
 Methysergide, S145
 Middle East, S20–S21, S46, S58
 Mind, S8, S79
 Mnestic block syndrome, S129
 Modern psychology, S100
 Molecular genetics, S8
 Monoamine neurotransmitters, S66
 Monoamine transmitters, S53
 Monotherapy, S134
 Mood, S77, S82
 Mood disorders, S5, S6, S67, S68, S88, S116
 Mood disorders in women, S44–S45
 Mood enhancing properties, S47
 Mood modulators, S66–S69
 Mood stabilizers, S38–S39, S75
 Mood symptoms, S66
 Morocco, S37
 Morphine, S113
 Morphine orlorazepam withdrawal, S149
 Mouse cerebral hemispheres, S131
 Multidisciplinary, S35–S37
 Multinational study, S154
 Multiple chemical sensitivity syndrome (MCS), S114
 Multiple receptor targets, S73
 Multiple synapses, S14
 Multisystems, S73–S75
 Myristoylated alanine-rich C kinase substrate, S38

N

N-Acetyl aspartyl glutamate, S85
 Nasal pathway to the brain, S27–S28
 National Alliance for the Mentally Ill, S11
 National Institute of Mental Health, S67
 Neocortex, S18
 Nepal, S148
 Neuroactive steroids, S26, S70–S73
 Neurocognitive functioning, S150
 NeuroCybernetic Prosthesis System, S144
 Neurodegenerative diseases, S127
 Neuroendocrine challenge, S115
 Neuroendocrine observations, S119
 Neuroendocrine responses, S51, S149

Neuroendocrine system, S91
 Neuroendocrine tests, S87–S89
 Neurogenesis, S38
 Neuroimaging, S64
 Neuroleptics, S107
 Neuromodulators, S74
 Neuronal changes, S8
 Neuropathogenesis, S133
 Neuropeptide Y (NPY), S61, S81, S118
 Neuropeptides, S61–S63
 Neur ophysiological evaluation, S132
 Neuroplasticity, S38
 Neuroprotection, S70
 Neuroprotective activity, S118
 Neuroprotective effects, S39
 Neuropsychiatry, S9–S11
 Neuropsychological pattern, S120
 Neuroreceptor PET/SPECT imaging, S155
 Neuroregulatory effects, S96
 Neurosteroidogenic enzymes, S70
 Neurosteroids, S14, S24–S27, S39, S40
 Neurotensin (NT), S62, S118
 Neurotransmitters, S74
 Neurotrophic actions, S78
 Neurotrophic factors, S62
 Nicotine, S134
 Nicotine nasal spray, S150
 Nitric oxide, S30
 NMDA receptors, S85
 Nocturnal thyroid-stimulating-hormone, S80
 Noncognitive psychiatric symptoms, S126
 Nongovernmental agencies, S10
 Noradrenaline, S62
 Norepinephrine, S69, S74
 Norepinephrine system, S1–S3
 Norepinephrinergic antidepressants, S130
 Normal ovarian endocrine, S97
 North Africa, S21
 Novel antidepressant interventions, S20
 Novel antipsychotic, S155

O

Obsessive compulsive disorder, S36, S98, S132
 Octreotide, S136
 Olanzapine, S150
 Operational arrangements, S9
 Oral contraceptives, S24, S24
 Osteoporosis, S34
 Outcome indicator, S142
 Ovarian function, S33
 Ovariectomy, S114
 Oxidative stress, S54

P

Panic anxiety, S135
 Panic disorder, S24, S157
 Parameters, S20
 Paroxetine, S133
 PAT brain mitochondria, S131
 Patient needs, S100
 Patient sampling, S42
 Pavlov, I.P., S152
 Peptides, S81
 Perimenopause, S98
 Peripheral nervous system, S70
 P-Chlorophenylalanine, S114
 Pharmacokinetic observations, S119
 Pharmacological therapies, S104, S153
 Phencyclidine, S83, S86
 Phenomenology, S123
 Pheromones, S27–S28
 Phosphatidylinositol, S3

Physical disorders, S155
 Physical stressors, S111
 Plasma cortisol levels, S105
 Plasma neurosteroid, S24
 Plasma prolactin, S150
 Polymorphisms, S154
 Postpartum cycloid, S97
 Postpartum depression, S116, S121
 Postpartum psychoses, S97
 Posttraumatic stress disorder (PTSD), S76, S105, S120, S121
 Potassium currents, S75
 Prediction, S87
 Prefrontal cortex, S84
 Pregnenolone, S39
 Premenstrual dysphoric disorder (PMDD), S45, S96, S97, S122, S154
 Premenstrual syndrome (PMS), S4, S45, S97, S112, S156
 Primary care, S98, S99, S100, S102
 PRIME-MD modules, S101
 Problem-oriented practical review, S100–S104
 Processing deficits, S128
 Progesterone, S41, S96, S116
 Progesterone metabolites, S40
 Progesterone therapy, S156
 Progestins, S66
 Progestogens, S41
 Prolactin release, S90
 Prolactin response, S144
 Prolactin-sparing antipsychotic drugs, S33
 Prolactinemia, S110
 Prozac, S142
 Psoriasis, S76
 Psychiatric care, S95
 Psychiatric diagnosis, S95
 Psychiatric disorders, S71, S140
 Psychiatry, S99, S100
 Psychiatry and gynecology, interface between, S96–S98
 Psychobiological reactions, S144
 Psychological disorders, S155
 Psychological evaluation, S132
 Psychoneuroendocrinology of stress, S29–S32
 Psychopathology, S36, S148
 Psychopharmacological approaches, S104
 Psychoses, S116
 Psychosexual development, S142
 Psychosocial maturity, S100
 Psychotherapeutic, S99
 Psychotic depression, S6
 Psychotic features, S120
 Psychotic major depression, S56
 Psychotropic drug action, S54
 Psychotropic drug use, S75
 Psychotropic medications, new, S12–S13
 Public health care, S15

Q

QA/QC parameters, S46
 Quality assurance, S7, S45–S46

R

R121919, S119, S149
 Raloxifene, S78
 Rat brain, S118
 Rat hippocampus, S125
 Rearing behavior, S63
 Reboxetine, S1, S2
 Recovery sleep, S82
 Refugees, S143

Rehabilitation, S143
 Religion, S99
 Religious practice, S37
 Repetitive transcranial magnetic stimulation, S20
 Reproductive events, S40
 Reproductive hormones, S65
 Reproductive-related disorders, S14
 Research agenda, S58
 Rhesus macaques, S113
 Rhett's Syndrome, S8
 Risk factor, S121
 Risperidone, S33, S120
 Russia, S143
 Russian hospitals, S142

S

Salivary cortisol levels, S153
 Schizophrenia, S12, S32–S35, S54, S55, S62, S83, S85, S86, S89, S92, S122, S123, S135, S150
 Schizophrenic patients, S107, S144, S150
 Schizotypy, S152
 Schwann cells, S70
 Scrizotypy, S151
 Seasonal bimodal pattern, S108
 Seasonal pattern of melatonin secretion, S108
 Secularization, S21
 Seizure, S90
 Selective estrogen receptor modulators (SERMs), S112
 Selective NRI, S2
 Selective serotonin reuptake inhibitors (SSRIs), S1, S42, S45, S56, S66
 Self reported sleep disorders, S109
 Self-hypnosis, S31
 Serotonergic antidepressants, S130
 Serotonergic system, S50
 Serotonergic transmission, S91
 Serotonin, S29, S62, S69, S73, S74, S84, S96
 Serotonin 2A receptor, S92
 Serotonin (5-HT), S110
 Serotonin deficiency, S112
 Serotonin receptors, S109
 Serotonin reuptake inhibitors, S122
 Serum levels, S140
 Sex difference, S44
 Sex steroid-related aggression, S122
 Sex steroid-related genes, S154
 Sex steroids, S96
 Sexology, S122
 Sex-specific events, S44
 Sexual disorders, S95, S122
 Sexuality, S94
 Signal transduction, S15
 Single receptor targets, S73

Sleep, S80–S83, S146
 Sleep deprivation, S80, S82, S146
 Sleeping disorders, S104
 Slow wave sleep, S81
 Social isolation, S148
 Social-Stress Disorders (SSD), S143
 Sodium valproate, S3, S135
 Somatic diagnoses, S101
 Somatic intersexuality, S142
 Somatic symptoms, S101
 Somatophorm disorders, S142
 Somatostatin, S81
 Specific behavioral actions, S42
 Specific estrogen receptors modulators, S78–S79
 Spiritual psychiatry, S35
 Spirituality, S99, S100
 Spirituality and mental health, S99–S100
 SSRIs, S112, S153
 St. John's Wort, S88
 Steroid hormone action, S71
 Steroids, S39–S42
 3 α -, 5 α -tetrahydroprogesterone, S25
 Stimulant abuse medications, S155
 Stress, S18, S29–S32, S50, S53, S59, S60, S61, S77, S101
 Stress control, S29
 Stress hormone systems, S6, S80
 Stress hormones, S129, S148
 Stress reduction, S4
 Stress responses, S13, S76
 Stress sensitization, S32
 Stress-induced disorders, S76–S77
 Stress-related hormones, S53
 Substance abuse, S102
 Substance P, S22–S23, S29, S110
 Substance P antagonists, S22–S23
 Subtype synapse, S14
 Suicidal ideation, S139
 Survival, S19
 Synapse-targeted psychopharmacology, S54–S56
 Synaptic plasticity, S17–S18, S53
 Synaptic spines, S53
 Synaptogenesis, S38

T

Tamoxifen, S78
 Target genes, S70
 TBE glucocorticoid receptor, S131
 Testosterone, S28, S56
 Testosterone levels, S136, S147
 Testosterone replacement, S147
 Therapeutic potential, S22
 Thyreotropin, S156
 Thyroid disturbances, S105
 Thyroid function, S67, S115

Thyroid hormone receptors, S69
 Thyroid hormones, S57, S66–S69
 Thyrotropin-releasing hormone, S57
 Thyroxine, S66
 T-maze, S36
 Tobaloperidol, S122
 Topiramate, S3
 Total sleep deprivation, S82
 Transcranial magnetic stimulation, S146
 Transcription factors, S52
 Transcultural Psychiatry, S35
 Transsexual patients, S120
 Treatment, S84
 Tricyclic antidepressants, S2, S42, S56
 Triiodothyronine, S57, S66, S68
 Triphenylethylenes, S79
 Trophic actions, S70
 Trophynotropine "Adement," S128
 Trophynotropine group, S127
 Tryptophan depletion, S115

U

UNICEF, S9
 Unipolar major depression, S68

V

Vagus nerve stimulation, S144
 Val108Met, S151
 Valproate augmentation, S134
 Vasoactive IC drugs, S122
 Vasopressin activity, S140
 Venlafaxine, S1
 Ventricular abnormality, S97
 Vigabatrin, S157
 Vitamin B12, S140
 Vomeronasal organ, S27
 Vomeroferins, S27
 Von Euler, S22
 Vulnerability to medical illness, S5
 Vulnerability to psychiatric illness, S5
 Vulnerability to substance abuse, S5

W

Wingless INT-1 signalling, S38
 Wistar rats, S135
 Word fluency, S107
 World Association of Social Psychiatry, S9
 World Federation of Biological Psychiatry, S9
 World Federation of Mental Health, S9
 World Health Organization, S9
 World Psychiatric Association, S9, S10, S58, S59